MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Two phase III studies have evaluated mesalazine (mesalamine) with MMX (Multi Matrix System) technology in patients with active mild-to-moderate ulcerative colitis.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Aliment. Pharmacol. Ther.

Title: Alimentary pharmacology & therapeutics

ISSN (Electronic): 1365-2036

ISSN (Print): 0269-2813

Publication date (Electronic): Jun 1 2008

Volume: 27

Issue: 11

Affiliations

[1 ] Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104-4283, USA. gary.lichtenstein@uphs.upenn.edu

Article

Publisher Item ID: APT3688

DOI: 10.1111/j.1365-2036.2008.03688.x

PubMed ID: 18363894

SO-VID: b000fdb9-d1cd-4682-b1b9-3e70306d798e

History

Data availability:

Comments

Comment on this article

scite_

Cited by 12

See all cited by